DexCom General and Administrative Expenses 2011-2026 | DXCM

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses DexCom

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.29 B	1.29 B	1.19 B	1.01 B	810 M	618 M	516 M	433 M	349 M	286 M	198 M	128 M	84.2 M	62.8 M	49.9 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.29 B	49.9 M	554 M

Quarterly General and Administrative Expenses DexCom

2026-Q1	2025-Q4	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
350 M	-	328 M	310 M	-	306 M	333 M	319 M	-	286 M	299 M	296 M	-	235 M	249 M	219 M	-	198 M	187 M	189 M	-	159 M	136 M	150 M	-	124 M	138 M	124 M	-	105 M	111 M	105 M	-	84.2 M	85.8 M	86.4 M	-	75.7 M	69.3 M	62.1 M	-	52.3 M	45.2 M	39.4 M	-	33.7 M	30.9 M	27.6 M	-	21.6 M	20.7 M	18.1 M	-	15.4 M	15.9 M	15.4 M	-	13.2 M	12.2 M	10.7 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
350 M	10.7 M	135 M

General and Administrative Expenses of other stocks in the Diagnostics research industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Enzo Biochem ENZ	21.7 M	-	-8.98 %	$ 14.8 K	USA
Centogene N.V. CNTG	46.7 M	-	-6.23 %	$ 30.6 M	Germany
Heska Corporation HSKA	64.1 M	-	-	$ 1.31 B	USA
DermTech DMTK	43.8 M	-	-11.32 %	$ 2.94 M	USA
Quest Diagnostics Incorporated DGX	1.97 B	$ 203.06	-0.38 %	$ 22.5 B	USA
Celcuity CELC	27.2 M	$ 88.55	-1.05 %	$ 4.14 B	USA
Akumin AKU	2.08 M	-	-17.87 %	$ 25.9 M	Canada
Co-Diagnostics CODX	9.06 M	$ 4.29	-8.72 %	$ 5.71 M	USA
Fulgent Genetics FLGT	117 M	$ 18.68	-0.53 %	$ 575 M	USA
Castle Biosciences CSTL	229 M	$ 20.7	-1.48 %	$ 600 M	USA
Aspira Women's Health AWH	7.96 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	21.3 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	16.1 M	-	-13.05 %	$ 7.29 M	USA
ICON Public Limited Company ICLR	780 M	$ 146.18	-2.49 %	$ 11.5 B	Irlanda
Oxford Immunotec Global PLC OXFD	22.3 M	-	-	$ 562 M	Britain
Guardant Health GH	211 M	$ 131.62	0.55 %	$ 16.5 B	USA
CareDx, Inc CDNA	108 M	$ 22.97	-2.92 %	$ 1.22 B	USA
Chembio Diagnostics CEMI	24.3 M	-	0.22 %	$ 16.8 M	USA
Check-Cap Ltd. CHEK	2.37 M	-	-	$ 9.42 M	Israel
Interpace Biosciences IDXG	9.48 M	$ 1.6	-3.03 %	$ 7.08 M	USA
Illumina ILMN	1.09 B	$ 160.97	-3.15 %	$ 25 B	USA
HTG Molecular Diagnostics HTGM	15.8 M	-	-20.0 %	$ 1.06 M	USA
Global Cord Blood Corporation CO	187 M	-	-	$ 399 M	China
National Research Corporation NRC	54.8 M	$ 18.79	-	$ 421 M	USA
Fluidigm Corporation FLDM	97.9 M	-	1.08 %	$ 308 M	USA
Natera NTRA	1.18 B	$ 212.07	-3.27 %	$ 29 B	USA
Genetic Technologies Limited GENE	4.16 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	126 M	-	0.12 %	$ 80.1 M	China
Pacific Biosciences of California PACB	141 M	$ 1.31	-2.96 %	$ 393 M	USA
Lantheus Holdings LNTH	275 M	$ 104.52	0.19 %	$ 7.05 B	USA
Charles River Laboratories International CRL	743 M	$ 187.51	-0.29 %	$ 9.29 B	USA
PRA Health Sciences, Inc. PRAH	453 M	-	-	$ 10.7 B	USA
Medpace Holdings MEDP	198 M	$ 467.34	-1.63 %	$ 13.5 B	USA
Exact Sciences Corporation EXAS	889 M	-	-	$ 19.8 B	USA
Mettler-Toledo International MTD	998 M	$ 1 131.49	-0.86 %	$ 23.3 B	Schweiz
NeoGenomics NEO	273 M	$ 11.15	-2.79 %	$ 1.43 B	USA
Myriad Genetics MYGN	257 M	$ 4.33	-6.48 %	$ 401 M	USA
Personalis PSNL	53.6 M	$ 9.59	1.8 %	$ 856 M	USA
Koninklijke Philips N.V. PHG	628 M	$ 26.46	1.34 %	$ 25.1 B	Niderland
Twist Bioscience Corporation TWST	247 M	$ 76.17	2.86 %	$ 4.56 B	USA
Senseonics Holdings SENS	52.5 M	$ 7.18	-2.05 %	$ 300 M	USA
QIAGEN N.V. QGEN	128 M	-	-	$ 10.6 B	Niderland
Soleno Therapeutics SLNO	132 M	-	-	$ 2.69 B	USA
Biomerica BMRA	2.98 M	$ 2.05	-1.91 %	$ 4.71 M	USA
Laboratory Corporation of America Holdings LH	2.22 B	$ 266.16	0.34 %	$ 22.1 B	USA
Thermo Fisher Scientific TMO	8.73 B	$ 469.34	-1.33 %	$ 177 B	USA
Trinity Biotech plc TRIB	28.8 M	$ 0.65	-3.7 %	$ 233 M	Irlanda
Motus GI Holdings MOTS	6.58 M	-	-34.28 %	$ 263 K	Israel
Neogen Corporation NEOG	218 M	$ 9.1	-1.57 %	$ 1.97 B	USA
Invitae Corporation NVTA	192 M	-	-	$ 21.2 M	USA